Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 GBX | +10.20% | -8.47% | -79.85% |
22/02 | Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024 | |
21/02 | FTSE 100 takes hit ahead of FOMC minutes | AN |
Sales 2023 * | 12.37M 15.5M 1.29B | Sales 2024 * | 36.3M 45.46M 3.79B | Capitalization | 10.56M 13.22M 1.1B |
---|---|---|---|---|---|
Net income 2023 * | -27M -33.81M -2.82B | Net income 2024 * | -10M -12.52M -1.04B | EV / Sales 2023 * | 1.08 x |
Net Debt 2023 * | 2.82M 3.54M 295M | Net Debt 2024 * | 16.74M 20.96M 1.75B | EV / Sales 2024 * | 0.75 x |
P/E ratio 2023 * |
-0.34
x | P/E ratio 2024 * |
-0.78
x | Employees | 27 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 43.82% |
Latest transcript on Shield Therapeutics plc
1 day | +10.20% | ||
1 week | -8.47% | ||
Current month | -33.33% | ||
1 month | -33.33% | ||
3 months | -78.40% | ||
6 months | -77.12% | ||
Current year | -79.85% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Madison
CEO | Chief Executive Officer | 57 | 01/21/01 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 47 | 16/01 |
David Childs
COO | Chief Operating Officer | - | 01/11/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 26/18/26 | |
Director/Board Member | 66 | 01/16/01 | |
Director/Board Member | 57 | 10/21/10 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1.35 | +10.20% | 8,345,835 |
25/24/25 | 1.225 | -7.55% | 8,963,337 |
24/24/24 | 1.325 | -7.02% | 2,958,047 |
23/24/23 | 1.425 | 0.00% | 700,061 |
22/24/22 | 1.425 | -3.39% | 705,761 |
Delayed Quote London S.E., April 26, 2024 at 09:05 pm IST
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-79.85% | 13.15M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- STX Stock